You are here: Industry Insights > NICE

News List

NICE backs Qarziba for children with high-risk neuroblastoma pharmatimes
July 16, 2018
NHS funding for EUSA’s Pharma’s Qarziba has been approved to treat children with high-risk neuroblastoma.
Ministers write letter to Vertex over Orkambi debate pharmatimespharmatimes
July 16, 2018
Ministers from the Department of Health have written a letter asking that Vertex bring negotiations with NHS England over access to cystic fibrosis drug Orkambi “to an urgent resolution”.
NICE backs procedure for benign prostate enlargement pharmatimes
July 13, 2018
The National Institute for Health and Care Excellence is now endorsing a procedure called Prostate Artery Embolisation (PAE) for NHS use to treat benign prostatic hyperplasia.
NICE backs Qarziba for children with high-risk neuroblastoma pharmatimes
July 13, 2018
NHS funding for EUSA’s Pharma’s Qarziba has been approved to treat children with high-risk neuroblastoma.
NICE turns down Darzalex combo for pre-treated multiple myeloma pharmatimes
July 13, 2018
Janssen says it is disappointed that NHS cost regulators are not backing NHS use of Darzalez (daratumumab) plus bortezomib and dexamethasone (DBd) for previously treated multiple myeloma in adults.
Final NICE nod for Keytruda in bladder cancer pharmatimes
July 12, 2018
MSD’s Keytruda has become the only immunotherapy to be funded by the NHS for the treatment of bladder cancer, following a final green light from cost regulators.
NICE backs Roche’s Tecentriq for pre-treated bladder cancer pharmatimes
July 12, 2018
Roche’s Tecentriq will be routinely available on the NHS in England and Wales to patients with advanced, pre-treated bladder cancer, following a nod from cost-regulators.
NICE backs use of dye for brain tumour removal pharmatimes
July 12, 2018
NICE has published new guidelines recommending use of a chemical dye to assist neurosurgeons in removing brain tumours.
NICE rejects Chiesi’s Lamzede pharmatimes
July 11, 2018
It is currently looking unlikely that Chiesi’s Lamzede will become routinely available on the NHS for patients with alpha-mannosidosis, after cost-regulators issued a preliminary rejection of the drug.
NICE issues decision on Mylotarg, Besponsa for leukaemia pharmatimes
July 11, 2018
The National Institute for Health and Care Excellence has issued draft guidelines backing restricted use of Pfizer’s Mylotarg for newly diagnosed acute myeloid leukaemia (AML), but has asked for more information on the firm’s Besponsa for a type of acute

Previous page 1 2 3 4 5 6 7 8 9 10 ... 41 42 Next page